company background image
FLGT

Fulgent Genetics NasdaqGM:FLGT Stock Report

Last Price

US$51.77

Market Cap

US$1.6b

7D

-18.8%

1Y

-47.8%

Updated

11 Aug, 2022

Data

Company Financials +
FLGT fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends0/6

FLGT Stock Overview

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally.

Fulgent Genetics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Fulgent Genetics
Historical stock prices
Current Share PriceUS$51.77
52 Week HighUS$109.55
52 Week LowUS$47.34
Beta1.47
1 Month Change-10.15%
3 Month Change-4.92%
1 Year Change-47.76%
3 Year Change407.55%
5 Year Change757.12%
Change since IPO463.94%

Recent News & Updates

Jul 26

Fulgent Genetics: Poised To Survive Its Post-Covid Hangover

Today, we take a deeper look at Fulgent Genetics, which has benefitted greatly from an explosion of Covid-19 testing revenue. The stock has sold off as fears around the coronavirus have ebbed. However, the company has a huge cash hoard to build up the other parts of its product portfolio. An investment analysis follows in the paragraphs below. "I used to advertise my loyalty and I don't believe there is a single person I loved that I didn't eventually betray." - Albert Camus, The Fall Today, we are putting Fulgent Genetics (FLGT) in the spotlight. The company has been a huge beneficiary of the pandemic. Covid-19 testing revenues powered a thirteen-fold increase in overall sales in the company's 4Q2020 earnings report as a good example of the magnitude of the benefit. Subsequently, the stock rocketed up from $10 a share in March 2020 to $160 in January 2021. Seeking Alpha However, as pandemic fears have ebbed considerably lately, the stock has sold off some 45% since late last year and is down nearly two-thirds from its all-time highs. Time to accumulate some shares in this diagnostic testing concern? An analysis follows below. Company Overview: Fulgent Genetics provides numerous tests and testing services and is based just outside of Los Angeles. Its product portfolio includes Covid-19, molecular diagnostic, and genetic testing. As noted above, the majority of revenues are coming from Covid-19 testing, its specialized oncology and other tests are what the company calls its 'core' revenue-generating part of the company. May Company Presentation The stock sells for around $58.00 a share and sports an approximate market capitalization of $1.75 billion. May Company Presentation First Quarter Results: On May 3rd, Fulgent posted first quarter numbers. The company had non-GAAP earnings of $5.12 a share on revenues of $320 million. Both top and bottom line results easily beat expectations. GAAP profits per share were $4.83. Revenue was down from nearly $360 million in the same period a year ago, solely as a result of a decrease from Covid testing. 'Core' revenue was up 59% to $25.1 million. Management raised its full-year guidance to $660 million worth of sales but took down full year non-GAAP income a buck to $6.00 a share. May Company Presentation Shortly after the quarter closed, Fulgent acquired Inform Diagnostics, a national independent pathology laboratory based in Irving, Texas, for $170 million. May Company Presentation Fulgent Genetics also purchased CSI Laboratories in 2021. May Company Presentation This triggered leadership to move up their estimate of 'core' revenue for FY2022 to approximately $175 million from $120 million previously. At its earnings call in early May, the leadership moved up its estimate for core revenue further to $180 million. May Company Presentation Analyst Commentary & Balance Sheet: Despite a decent-sized market cap, Fulgent Genetics gets short shrift from Wall Street. On January 25th, maintained its Buy rating on FLGT but lowered its price target from $141 to $125 a share. In late May, Piper Sandler reissued its Buy rating after meeting with management. Piper's analyst stated that he was: Impressed with the company's core growth, potential in its COVID business, and "optionality" with its $1.1B in cash. The analyst believes Fulgent is setting itself up to add growth via acquisitions, particularly as other labs struggle with cash management."

Jul 21
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

With a price-to-earnings (or "P/E") ratio of 4x Fulgent Genetics, Inc. ( NASDAQ:FLGT ) may be sending very bullish...

Shareholder Returns

FLGTUS HealthcareUS Market
7D-18.8%1.0%1.3%
1Y-47.8%15.6%-11.7%

Return vs Industry: FLGT underperformed the US Healthcare industry which returned 15.8% over the past year.

Return vs Market: FLGT underperformed the US Market which returned -11.6% over the past year.

Price Volatility

Is FLGT's price volatile compared to industry and market?
FLGT volatility
FLGT Average Weekly Movement7.6%
Healthcare Industry Average Movement8.9%
Market Average Movement7.8%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: FLGT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: FLGT's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011645Ming Hsiehhttps://www.fulgentgenetics.com

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2.

Fulgent Genetics, Inc. Fundamentals Summary

How do Fulgent Genetics's earnings and revenue compare to its market cap?
FLGT fundamental statistics
Market CapUS$1.57b
Earnings (TTM)US$392.38m
Revenue (TTM)US$925.15m

4.0x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FLGT income statement (TTM)
RevenueUS$925.15m
Cost of RevenueUS$243.39m
Gross ProfitUS$681.76m
Other ExpensesUS$289.38m
EarningsUS$392.38m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)12.96
Gross Margin73.69%
Net Profit Margin42.41%
Debt/Equity Ratio1.6%

How did FLGT perform over the long term?

See historical performance and comparison